Two Hands Corp (TWOH): I expect trendyrade to be fully im...

I expect trendyrade to be fully immersed in

Hercules1 · 2025-04-03T21:53:02.0400000Z

I expect trendyrade to be fully immersed in a city sewer right about now rinsing his sorry ass.

Play Episode

7min

Proactive - Interviews for investors

Titan Mining reports record 2024 production, expands resources

Titan Mining President Rita Adiani joined Steve Darling from Proactive to discuss the company’s year-end results, highlighting record production and strong financial performance in 2024. The company met the upper end of its production guidance, while costs were 10% lower than the low end of its all-in sustaining cost (AISC) guidance. In Q4 2024, Titan Mining produced 21.7 million pounds of payable zinc, marking a 56% increase compared to Q4 2023. Total full-year 2024 production reached 59.5 million pounds. The company also posted Q4 revenues of $26.3 million, representing a 318% increase from Q3 2024 and a 241% increase from Q4 2023. Adiani also shared updates on the company’s mineral resource expansion, noting that Titan completed an updated mineral resource estimate and extended the mine life for ESM’s zinc operations until 2033. The updated estimate reports a 22% increase in measured and indicated contained zinc pounds compared to the 2020 resource estimate. In addition to its zinc operations, Titan completed a maiden mineral resource estimate for the Kilbourne Graphite Project. The project now holds an open-pit constrained inferred mineral resource of 22 million U.S. short tons, with an average grade of 2.91% (Cg), containing 653,000 tons of graphite at a 1.50% cut-off grade. #proactiveinvestors #titanminingcorporation #tsx #ti #otcqb #timcf #TitanMining #ZincProduction #GraphiteMining #BatteryMetals #CriticalMinerals #MiningStocks #TSX #RitaAdiani #EVMaterials #GraphiteUSA #MiningExpansion #AgustaGroup #ProactiveInvestors

Proactive - Interviews for investors

Allergy Therapeutics turns the corner, targets market launches

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) chief executive Manuel Llobet and chief financial officer Shaun Furlong talked with Proactive's Stephen Gunnion about the company’s financial turnaround and ongoing progress across key clinical programs. Allergy Therapeutics reported a return to operating profit before R&D, exceptional and fundraising costs, supported by topline growth and strict cost control. Llobet highlighted that the company saw a 4% constant currency growth in euro-denominated sales—double that of the previous period—driven by improved supply chains and the strong performance of new and registered products. “The top line is good in terms of quantity and quality,” he said. Furlong added that these results, along with the recent financial restructuring, demonstrate a clear path to sustainable health. The company’s cash position rose to £21.7 million at the end of December from £12.9 million in June, aided by external funding and shareholder support. On the clinical side, Llobet described the Grass MATA MPL program as a potential “game changer”, with a Marketing Authorisation Application submitted in Germany. He also noted the progress of the Polyvac Peanut program, which aims to offer a short-course treatment capable of disease modification, differentiating it from current therapies. The company remains focused on progressing these pipeline assets while maintaining financial discipline. For more exclusive interviews, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications to stay updated. #AllergyTherapeutics #BiotechNews #Immunotherapy #GrassMATA #PeanutAllergy #VaccineDevelopment #R&D #Pharmaceuticals #FinancialResults #InvestorUpdates #ProactiveInvestors

Proactive - Interviews for investors

Solvonis Therapeutics engages PharmaVentures to support key AUD assets

Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive about the company's strategic move to commercialise two clinical-stage assets targeting alcohol use disorder (AUD). Tennyson explained that Solvonis has engaged PharmaVentures to support valuation and potential out-licensing for two lead programs—AWKN-001 and AWKN-002. PharmaVentures was chosen based on its three-decade track record in biopharma M&A advisory, with over 1,000 deals completed. Tennyson noted, “We’ve selected them for three reasons: their expertise, their experience, and their reach.” The two assets originated from Solvonis's planned acquisition of Awakn Life Sciences, a transaction expected to be completed in the second quarter. AWKN-001, now in Phase 3 trials, targets severe AUD in the UK and EU. PharmaVentures estimates the asset could yield around £60 million in upfront and milestone payments, plus significant double-digit royalties. AWKN-002, focused on moderate to severe AUD in the US, is in Phase 2B planning. This program could generate approximately £150 million, based on comparable transactions. Tennyson emphasised the unmet medical need, citing a 75% relapse rate within a year for current AUD treatments. “That represents a significant commercial opportunity for Solvonis,” he said. For more interviews like this, visit Proactive's YouTube channel. Give this video a like, subscribe, and enable notifications to stay updated. #SolvonisTherapeutics #AlcoholUseDisorder #BiotechNews #ClinicalTrials #AWKN001 #AWKN002 #AddictionTreatment #PharmaVentures #MentalHealthInnovation #BiopharmaDeals #InvestorUpdate #HealthcareStocks #Phase3Trial #Outlicensing #Q2Milestones

Proactive - Interviews for investors

Orion Minerals CEO on Prieska & Okiep DFS milestones as company enters next phase

Orion Minerals Ltd (ASX:ORN, JSE:ORN) managing director and CEO Errol Smart talked with Proactive's Stephen Gunnion about the completion of definitive feasibility studies (DFS) for both the company’s flagship Prieska copper-zinc project and the Flat Mines project at its Okiep copper project. Smart described this as a pivotal moment, noting, “It’s taken us eight years now to put them together… but it's really a great outcome for us.” The studies confirm robust development pathways for both operations in South Africa's Northern Cape, with both projects fully permitted and development-ready. Smart said Orion is in a unique position globally, with capital intensity figures below key industry benchmarks. The combined production profile is expected to deliver 30,000 tonnes of copper annually at around $9,500 per tonne capital intensity, placing the company in the lower quartile of the cost curve. The Prieska project will follow a two-phase development plan, with a modest $25 million start-up operation set to begin production within 13 months, followed by a ramp-up to full-scale output. Smart also confirmed that discussions are underway with strategic partners, including the Industrial Development Corporation and offtake-related financiers. He highlighted that smelters and traders are actively seeking long-term copper supply, saying, “We represent a very interesting opportunity for them, with certainty.” Visit Proactive’s YouTube channel for more company updates and interviews. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #OrionMinerals #CopperMining #PrieskaProject #OkiepProject #BaseMetals #MiningInvestment #FeasibilityStudy #SouthAfricaMining #CopperProduction #ZincProduction

Followers	1014
Posts	44706
Boards Moderated	0
Alias Born	03/17/2014

Volume:	205,696,951
Day Range:	0.004 - 0.0072
Bid:	0.0057
Ask:	0.0061
Last Trade Time:	3:59:46 PM EDT
Total Trades:	2,008

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

TWOH Detailed Quote

Recent TWOH News

More TWOH News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent TWOH News

Go Ad-Free